SYNTap Biomarker Test helps doctors distinguish Parkinson's Disease from Parkinsonism in early stages
Retrieved on:
Wednesday, April 6, 2022
Linda, Substantia nigra, Chittagong Veterinary and Animal Sciences University, Southern Illinois University School of Medicine, Neurology, Diagnosis, Neurodegeneration, Oregon Health & Science University, Movement disorders, Dopamine, Body, Synuclein, School, Oregon Health Plan, PD, Basal ganglia, History, Alzheimer's disease, Neurological disorder, Progressive supranuclear palsy, Autopsy, Parkinson's disease, Time, Physician, Amprion, Movement, SAN, FDA, Patient, Disease, Medical imaging, Palladium, Pharmaceutical industry, Medical device, Parkinsonism
SAN FRANCISCO, April 6, 2022 /PRNewswire-PRWeb/ -- PD affects 10 million people globally. About one million Americans live with PD, and 60,000 new cases are added each year. Unfortunately, despite billions of spending in drug R&D over the past three decades, there is no cure for Parkinson's–yet.
Key Points:
- For the first time in history, Amprion's breakthrough SYNTap Biomarker Test can help doctors effectively distinguish Parkinson's Disease (PD) from Parkinsonism early.
- Clinical diagnosis of PD is challenging, particularly at early stages when treatments are likely to be more effective.
- For the first time in history, Amprion's breakthrough SYNTap Biomarker Test can help doctors effectively distinguish PD from Parkinsonism in early stages.
- Our SYNTap Biomarker Test helps doctors diagnose Parkinson's, Lewy Body Dementia, and Alzheimer's with Lewy Bodies.